Evolus, Inc. (0K16.L)

USD 14.58

(0.16%)

Revenue Summary of Evolus, Inc.

  • Evolus, Inc.'s latest annual revenue in 2023 was 202.08 Million USD , up 35.98% from previous year.
  • Evolus, Inc.'s latest quarterly revenue in 2024 Q2 was 66.9 Million USD , up 12.77% from previous quarter.
  • Evolus, Inc. reported a annual revenue of 148.61 Million USD in annual revenue 2022, up 49.1% from previous year.
  • Evolus, Inc. reported a annual revenue of 99.67 Million USD in annual revenue 2021, up 76.29% from previous year.
  • Evolus, Inc. reported a quarterly revenue of 66.9 Million USD for 2024 Q2, up 12.77% from previous quarter.
  • Evolus, Inc. reported a quarterly revenue of 202.08 Million USD for 2023 FY, up 35.98% from previous quarter.

Annual Revenue Chart of Evolus, Inc. (2023 - 2015)

Historical Annual Revenue of Evolus, Inc. (2023 - 2015)

Year Revenue Revenue Growth
2023 202.08 Million USD 35.98%
2022 148.61 Million USD 49.1%
2021 99.67 Million USD 76.29%
2020 56.54 Million USD 61.89%
2019 34.92 Million USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%

Peer Revenue Comparison of Evolus, Inc.

Name Revenue Revenue Difference
Thermo Fisher Scientific Inc. 42.85 Billion USD 99.528%
Dynavax Technologies Corporation 232.28 Million USD 13.001%
Illumina, Inc. 4.5 Billion USD 95.513%
IQVIA Holdings Inc. 14.98 Billion USD 98.651%
Biogen Inc. 9.83 Billion USD 97.945%
Iovance Biotherapeutics, Inc. 1.18 Million USD -16896.215%
Mettler-Toledo International Inc. 3.78 Billion USD 94.666%
Sarepta Therapeutics, Inc. 1.24 Billion USD 83.747%
Supernus Pharmaceuticals, Inc. 607.52 Million USD 66.736%
Waters Corporation 2.95 Billion USD 93.165%
Perrigo Company plc 4.65 Billion USD 95.659%
uniQure N.V. 15.84 Million USD -1175.548%
Agios Pharmaceuticals, Inc. 26.82 Million USD -653.402%
Amicus Therapeutics, Inc. 399.35 Million USD 49.397%
Atara Biotherapeutics, Inc. 8.57 Million USD -2257.226%
bluebird bio, Inc. 29.49 Million USD -585.104%
Cara Therapeutics, Inc. 20.96 Million USD -863.778%
Imunon, Inc. - USD -Infinity%
Myriad Genetics, Inc. 678.4 Million USD 70.212%
Neurocrine Biosciences, Inc. 1.88 Billion USD 89.291%
Nektar Therapeutics 90.12 Million USD -124.235%
Editas Medicine, Inc. 78.12 Million USD -158.675%
Verastem, Inc. - USD -Infinity%
Walgreens Boots Alliance, Inc. 147.65 Billion USD 99.863%
Corbus Pharmaceuticals Holdings, Inc. - USD -Infinity%
Heron Therapeutics, Inc. 127.04 Million USD -59.067%
Unity Biotechnology, Inc. - USD -Infinity%
BioMarin Pharmaceutical Inc. 2.41 Billion USD 91.647%
Sangamo Therapeutics, Inc. 176.23 Million USD -14.67%
Adicet Bio, Inc. - USD -Infinity%
Aclaris Therapeutics, Inc. 31.24 Million USD -546.693%
Regeneron Pharmaceuticals, Inc. 13.11 Billion USD 98.459%
Esperion Therapeutics, Inc. 116.33 Million USD -73.711%
FibroGen, Inc. 147.75 Million USD -36.773%
Agilent Technologies, Inc. 6.83 Billion USD 97.043%
OPKO Health, Inc. 863.49 Million USD 76.597%
Homology Medicines, Inc. -6.65 Million USD 3138.415%
Geron Corporation 237 Thousand USD -85167.932%
Alnylam Pharmaceuticals, Inc. 1.82 Billion USD 88.947%
Exelixis, Inc. 1.83 Billion USD 88.958%
Viking Therapeutics, Inc. - USD -Infinity%
Anavex Life Sciences Corp. - USD -Infinity%
Intellia Therapeutics, Inc. 36.27 Million USD -457.092%
Zoetis Inc. 8.54 Billion USD 97.635%
Axsome Therapeutics, Inc. 270.6 Million USD 25.32%
Abeona Therapeutics Inc. 3.5 Million USD -5673.857%
Vertex Pharmaceuticals Incorporated 9.86 Billion USD 97.952%
Kala Pharmaceuticals, Inc. - USD -Infinity%
Ionis Pharmaceuticals, Inc. 787.64 Million USD 74.343%
Corcept Therapeutics Incorporated 482.37 Million USD 58.106%
Halozyme Therapeutics, Inc. 829.25 Million USD 75.63%
Blueprint Medicines Corporation 249.38 Million USD 18.965%
Insmed Incorporated 305.2 Million USD 33.788%
TG Therapeutics, Inc. 233.66 Million USD 13.514%
Incyte Corporation 3.69 Billion USD 94.532%
Emergent BioSolutions Inc. 1.04 Billion USD 80.741%